-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the drug network database shows that AstraZeneca submitted Ohitini's second new indication", "first-line treatment for epidermal growth factor receptor (EGFR) gene mutation of advanced non-small cell lung cancer (NSCLC) patients" listing application, has entered the "in approval" state, will soon be approved for listing.
screenshot of search results in the database of the drug
it is understood that AstraZeneca's new indications have been released as a priority review on 24 December 2018. The indication was approved in the United States in April 2018.
Ochtinib, the world's first three-generation targeted drug to be listed, developed by AstraZeneca as a three-generation EGFR TKI (epidermal growth factor receptor tyrosine kinase inhibitor), Ochtinib acts on a specific gene mutation (T790M) that is resistant to a generation or second generation of targeted drugs.
AstraZeneca's financial results show that in 2018, Ochtini's sales in China reached 1.85 billion yuan in the first three quarters, with full-year sales of nearly 2 billion yuan. The first-quarter 2019 results also showed Ochtini with top sales, with revenue of $630 million.
on the other hand, Ohitini was included in Class B in October 2018, with a medicship payment standard of 510 yuan (80 mg/tablet), 300 yuan (40 mg/tablet), limited to the limit of the payment limit to the progression of disease due to EGFR-TKI treatment or treatment, and confirmed the presence of EGFR T790M mutation of local advanced or non-adult cell disease.
March 22, 2017, the National Drug Administration approved AstraZeneca's Ochitinib tablets for use in patients with localized or non-small cell lung cancer (NSCLC) who have been treated with or after treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) and have been confirmed to have an EGFR T790M mutation.
now that the new indications are being approved, it is expected to provide more options for lung cancer patients.
.
